Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants

Overview

To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.

Full Title of Study: “Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2019

Interventions

  • Drug: Omegaven
    • Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
  • Drug: Omegaven
    • Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
  • Drug: Omegaven
    • If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.

Arms, Groups and Cohorts

  • Experimental: 1
    • Drug: Omegaven

Clinical Trial Outcome Measures

Primary Measures

  • Death associated with liver disease
    • Time Frame: Maximum 2 years
    • Those patients with death only associated with liver diseasepre-treatment period and the expected rate of growth.

Secondary Measures

  • Liver transplantation
    • Time Frame: Maximum 2 years
  • Growth over time as determined by weight in grams.
    • Time Frame: Maximum 2 years
  • Growth over time as measured by length in cm.
    • Time Frame: Maximum 2 years
  • Growth over time as measured by head circumference in cm.
    • Time Frame: Maximum 2 years
  • Development of essential fatty acid (EFA) deficiency as measured by triene:tetraene ratio in those with prolonged NPO status.
    • Time Frame: Maximum 2 years
  • Hyperlipidemia as measured by triglyceride level
    • Time Frame: Maximum 2 years

Participating in This Clinical Trial

Inclusion Criteria

1. Critically ill infants with either a known anatomic short gut (greater than 50% of the bowel removed) or known severe dysmotility of the gut reflecting non-functional gut similar to anatomic short gut will be offered Omegaven® when their direct bilirubin reaches 2 mg/dL. Infants who do not meet the above criteria for anatomic or dysfunctional short gut will be allowed to receive Omegaven® when their direct bilirubin reaches 4 mg/dL. The qualifying measurements of 2 mg/dL or 4 mg/dL direct bilirubin must be consecutive and obtained at least 24 hours apart. 2. Be expected to require intravenous nutrition for at least an additional 28 days 3. Patient must have documented failure of or ineligibility for the following therapies to prevent progression of PNALD:

  • Reduction of Intralipid® to 1 g/kg/day – Limiting trace minerals including copper and manganese – Initiation and use of Ursodiol – Cycling of parenteral nutrition – Advancement of enteral feedings 4. Parental informed consent must be signed. Exclusion Criteria:

1. Have a congenitally lethal condition (e.g. Trisomy 13). 2. Have clinically severe bleeding not able to be managed with routine measures. 3. Have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis. 4. Have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves. 5. Has culture positive sepsis

Gender Eligibility: All

Minimum Age: 14 Days

Maximum Age: 2 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pediatrix
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kaashif Ahmad, MD, Principal Investigator, Pediatrix

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.